Estuary Biotherapeutics
Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.
$93MSeries A
ParticipantUE
UPMC Enterprises
Activity from announced rounds
Activity in this selectionOct 31, 2026 · Oct 1, 2026
UPMC Enterprises is the organization identified in its own RAAPID, BrainCheck and ai3Bio materials.
Recorded funding activity
RAAPID supplies healthcare risk-adjustment software. Ai3Bio develops immune-cell-targeted medicines. The pending ai3Bio relation stays in draft, and the organization remains separate from UPMC and the University of Pittsburgh.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $93M 1 disclosed · full round size, not this investor’s share